H. Lee Moffitt Cancer Center and Research Institute: clinical-trial pipeline
H. Lee Moffitt Cancer Center and Research Institute is the sponsor of 538 clinical trials in ClinicalTrials.gov and the EU CTIS portal; 136 are not yet finished and 0 were first posted in the last 90 days. Source: Arcadium Data, data as of .
Trials by phase
| Phase | Trials |
|---|---|
| Phase 2 | 175 |
| Not applicable | 172 |
| Phase 1 | 111 |
| Phase 1/2 | 46 |
| Early phase 1 | 27 |
| Phase 3 | 3 |
| Phase 2/3 | 2 |
| Phase 4 | 2 |
Trials by status
| Status | Trials |
|---|---|
| Completed | 303 |
| Recruiting | 69 |
| Terminated | 65 |
| Active, not recruiting | 62 |
| Withdrawn or not authorised | 22 |
| Suspended or halted | 7 |
| Not yet recruiting | 5 |
| Unknown | 5 |
Condition areas
| Area | Trials |
|---|---|
| Oncology | 474 |
| Nephrology and urology | 59 |
| Gastroenterology and liver | 57 |
| Dermatology | 28 |
| Rare and genetic diseases | 22 |
| Haematology | 17 |
| Infectious disease and vaccines | 15 |
| Metabolic and endocrine (diabetes, obesity) | 14 |
| Women's health and obstetrics | 14 |
| Neurology | 9 |
| Musculoskeletal | 8 |
| Respiratory | 8 |
Countries
| Country | Trials |
|---|---|
| United States | 523 |
| Puerto Rico | 9 |
| Germany | 1 |
| Cambodia | 1 |
| Mexico | 1 |
| South Africa | 1 |
Open trials
The 25 most recently changed open trials.
| Registry id | Title | Phase | Status | Countries |
|---|---|---|---|---|
| NCT05014282 | Automated Video-Assisted Smoking Treatment for People Living With HIV | Not applicable | Active, not recruiting | United States |
| NCT04996823 | Axitinib + Ipilimumab in Advanced Melanoma | Phase 2 | Active, not recruiting | United States |
| NCT07194044 | Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes | Phase 1 | Recruiting | United States |
| NCT03511196 | Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer | Early phase 1 | Active, not recruiting | United States |
| NCT06350318 | Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas | Phase 2 | Recruiting | United States |
| NCT05581030 | CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) | Phase 1 | Recruiting | United States |
| NCT06497569 | Support Through Remote Observation and Nutrition Guidance Program for Individuals With Gastroesophageal Cancer | Not applicable | Recruiting | United States |
| NCT06691035 | Immunologic Targeting of ESR1 Receptor for Hormone Receptor Expressing Metastatic Breast Cancer | Phase 1 | Active, not recruiting | United States |
| NCT05732961 | Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms | Phase 2 | Active, not recruiting | United States |
| NCT05681780 | Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC | Phase 1 | Recruiting | United States |
| NCT06963346 | Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents | Phase 1 | Recruiting | United States |
| NCT04760847 | Intermittent Fasting for Pancreatitis | Not applicable | Not yet recruiting | United States |
| NCT06409390 | Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer | Phase 2 | Recruiting | United States |
| NCT07686250 | Evaluation and Outcomes of SAVI Scout MD for Localized Breast Surgery | Phase 2 | Recruiting | United States |
| NCT04745559 | Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy | Phase 2 | Active, not recruiting | United States |
| NCT03611738 | Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC | Phase 1 | Active, not recruiting | United States |
| NCT06734130 | Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer | Phase 2 | Active, not recruiting | United States |
| NCT05558124 | CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML | Phase 1 | Recruiting | United States |
| NCT06423963 | Remote Exercise and Nutritional Prehabilitation for Pancreatic Cancer | Not applicable | Recruiting | United States |
| NCT07638150 | PRehabilitation Intervention to Modify Eating for Breast Cancer Patients (PRIME) | Not applicable | Not yet recruiting | United States |
| NCT06597565 | A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC | Phase 2 | Recruiting | United States |
| NCT05024552 | Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML | Phase 1 | Recruiting | United States |
| NCT07249775 | A First-in-Human Study of FID-022 in Solid Tumor Patients | Not applicable | Recruiting | United States |
| NCT07218848 | ProSalud in Latinos Living in Rural/Agricultural Communities Within Moffitt's Catchment Area | Not applicable | Active, not recruiting | United States |
| NCT05070403 | Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma | Phase 2 | Active, not recruiting | United States |
All sponsors: clinical-trial pipeline by sponsor.
Track a sponsor's pipeline
The API returns the same trials by sponsor website, phase, status, condition and country with a change feed, joined to hiring and public contract awards. Try it without a key on one sponsor.
Sources: ClinicalTrials.gov (U.S. National Library of Medicine, public domain) and the EU Clinical Trials Information System public portal (European Medicines Agency), data as of 2026-10-25. A trial that one register cites in the other is shown once. Organisation-level data only: investigators, contact persons and site names are not stored, and a sponsor that could be a private person is withheld. Sponsor-to-website matches are made by name and can be wrong; check the register before relying on a record. Independent of the NLM, NIH and EMA.
Cite as: Arcadium Data, "H. Lee Moffitt Cancer Center and Research Institute clinical trials: 136 open, 5 in phase 3", https://arcadiumdata.io/clinical-trials/sponsor/h-lee-moffitt-cancer-center-and-research-institute/, data as of 2026-10-25.